Cadila inks agreement with Norway based Serca Pharmaceuticals for better treatment of heart patients
Cadila, a research-based pharma group in India enters into an agreement with Norway based Inven2’s startup company, Serca Pharmaceuticals. The agreement was recently signed with Cadila. The signing took place in New Delhi in India in connection with the official state visit to Erna Solberg. The agreement is about developing a new and better treatment for patients afflicted with heart attack.
Basis the agreement Cadila will develop a new treatment for patients afflicted with heart attack, which SERCA Pharmaceuticals can advance to global markets. The new drug is based on an invention made by Professor KjetilTaskén and co-workers at the University of Oslo and Oslo University Hospital.
Serca Pharmaceuticals work is based on breakthrough science from KjetilTaskens Group at the University of Oslo (UiO). Serca is now building up the company in Norway. Serca’s drug is aiming to help patients from getting secondary damage from cardiac disease, which is an unmet Medical need. SERCA Pharmaceuticals will develop a drug treatment for injuries that occur when treating myocardial infarction.
Inven2 is the largest contributor in Norway within the field of commercialization of research, owned by the University of Oslo and Oslo University Hospital, Norway’s largest and leading university and hospital representing pioneering research.
